Dash Bio, a biotechnology company building automated bioanalysis infrastructure for drug development, has raised $30 million in Series A funding. The round was led by Oak HC/FT, with participation from Freestyle Capital, Swift Ventures and existing investors. The funding will support commercial expansion, laboratory capacity, software development and new assay capabilities.
Accelerating bioanalysis with automation
Dash Bio provides an automated bioanalysis platform designed to speed up preclinical and clinical testing. Its 24,000-square-foot GLP laboratory combines robotics with a proprietary laboratory operating system to automate workflows across multiple assay types, reducing manual processes and shortening turnaround times from months to days.
The platform also offers transparent pricing and full digital traceability, helping pharmaceutical and biotechnology companies improve planning and accelerate drug development.
Expanding platform and laboratory capabilities
Since launching commercially, Dash Bio has secured contracts with more than 30 customers, including four of the world's top 15 pharmaceutical companies. The new funding will expand laboratory capacity, broaden assay offerings, enter new product categories and strengthen the company's proprietary software platform.
Dave Johnson, Co-founder and CEO of Dash Bio, said: “Sponsors and patients can't wait. We built Dash on a deep conviction: the pace of drug development should be set by the science, not by queues and legacy process. Our goal is to push deliverable timelines to the very limits of the underlying chemistry, physics, and biology. Everything about how we operate, from our tech-first approach to our transparent, fixed pricing, is built to serve that goal, and ultimately to get medicines to patients faster.”
Andy Smith, Partner at Oak HC/FT, added: “In less than two years, the Dash team has built a GLP-compliant, fully automated bioanalysis platform that the industry's largest drug developers are already adopting. The team’s background architecting the digital and automation infrastructure at Moderna during one of the most consequential scale-ups in modern history brings a playbook and level of experience to productizing and scaling infrastructure for science that very few founders in this space can match.”